Guangzhou's Huangpu district hit a significant milestone, reaching a fixed-asset investment that exceeds 100 billion yuan ($15.38 billion) in the first half of this year, leading the ranks among China's economic development zones.
As a stronghold for Guangzhou's real economy and technological innovation, Huangpu is making its mark in the national economic landscape. BeiGene, representing the biopharmaceutical sector in the district, has reported a robust performance in its United States stock market filings. It also successfully launched its innovative cancer medicine in the US market.
Strategic emerging industries in Huangpu, such as new energy vehicles and biopharmaceuticals, continue to attract investments and fuel regional industrial advancement.